Nutriband Inc. (NASDAQ: NTRB)

The QualityStocks Daily Newsletter would like to spotlight Nutriband Inc. (NASDAQ: NTRB).

Nutriband (NASDAQ: NTRB) announced it has entered into an exclusive distribution agreement with Costa Rica-based Innomedica for AVERSA Fentanyl, upon approval, and all sports tape products manufactured at its Pocono Pharmaceutical/Active Intell subsidiary. Under the agreement, Innomedica will oversee and finance regulatory approvals as the products advance toward launch. Nutriband's AVERSA abuse-deterrent transdermal technology is designed to incorporate aversive agents into patches to deter abuse, diversion and misuse of drugs with abuse potential, supported by a broad international patent portfolio.

To view the full press release, visit https://ibn.fm/2YOl8

Nutriband Inc. (NASDAQ: NTRB) is engaged in the development of a portfolio of transdermal pharmaceutical products. The company’s AVERSA™ technology can be incorporated into any transdermal patch and includes aversive agents to prevent abuse, diversion, misuse and accidental exposure to drugs with abuse potential, specifically opioids.

AVERSA technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, such as fentanyl, while making sure that these drugs remain accessible to patients who need them. The technology is covered by a broad intellectual property portfolio with patents granted in the United States, Europe, Japan, Korea, Russia, Canada, Mexico, Australia, and China, with recent extensions into Macao.

The company’s business model is to apply its transdermal technology to existing FDA-approved drugs with a goal of improving safety, efficacy and patient comfort while qualifying for a limited-development regulatory pathway that reduces the number of clinical trials required for approval of new drugs.

Nutriband has three subsidiaries, including 4P Therapeutics, its clinical and regulatory subsidiary; Pocono Pharmaceutical, a contract manufacturer for a wide range of clients; and Active Intelligence, a developer of sports recovery products. This ownership of manufacturing and clinical development capabilities drastically reduces costs for AVERSA and other technologies.

In April 2024, Nutriband announced that the company had been engaged by and received a first order from Fit For Life Group, a major brand license holder. A fully executed supplier agreement is expected to follow. Nutriband’s wholly owned Active Intelligence subsidiary will act as manufacturer.

In February 2025, the company formalized its product development partnership with Kindeva Drug Delivery through a long-term exclusive agreement. The collaboration supports the commercial pathway for AVERSA Fentanyl by leveraging Kindeva’s FDA-approved transdermal fentanyl patch system.

The company is headquartered in Orlando, Florida.

Products

Nutriband’s lead product candidate is AVERSA Fentanyl, an abuse-deterrent fentanyl transdermal patch. The company announced in March 2024 that it will submit a New Drug Application to the U.S. Food and Drug Administration seeking approval to market AVERSA Fentanyl. In subsequent updates, Nutriband confirmed that the NDA submission remains the company’s primary focus and is backed by a strong cash position.

Nutriband has partnered with Kindeva Drug Delivery, a leading global contract development and manufacturing organization, to incorporate Nutriband’s AVERSA abuse-deterrent transdermal technology into Kindeva’s FDA-approved transdermal fentanyl patch system. Because Nutriband’s abuse-deterrent technology is incorporated into the fentanyl patch but is physically separate from and does not come in contact with the drug layer, the clinical trials typically needed to demonstrate safety and efficacy for a new drug formulation would not be required.

In support of this commercialization strategy, Nutriband closed an $8.4 million private placement in April 2024 to fund development activities related to AVERSA Fentanyl. The company also licensed Bitrex®, a widely used aversive agent, to enhance the deterrent profile of its patch formulation.

AVERSA Fentanyl has the potential to be the first and only abuse deterrent patch approved anywhere in the world. The company plans to seek an expedited review by the FDA, as has been granted for certain abuse-deterrent oral opioid products, which shortens the regulatory review period to six months from the conventional 10-month FDA review cycle for NDAs.

Nutriband’s AVERSA product development pipeline also includes abuse deterrent versions of currently approved and marketed transdermal patches containing buprenorphine, an opioid used to treat opioid use disorder, and methylphenidate, a central nervous system stimulant used in the treatment of attention deficit hyperactivity disorder (ADHD). Both are labeled with FDA-required warnings for the risk of abuse and misuse, as well as warnings against accidental exposure.

Market Opportunity

Nutriband cites a market analysis report from Boston-based Health Advances, a healthcare and life sciences consulting firm. According to the report, upon FDA approval, AVERSA Fentanyl has the potential to reach peak annual sales of $200 million in the U.S.

The company further states that, should non-abuse-deterrent transdermal fentanyl products lose FDA marketing approval, AVERSA Fentanyl would have greater pricing flexibility and would have the potential to generate more than $500 million in annual revenue.

Management Team

Gareth Sheridan is Co-Founder and CEO of Nutriband. He was Ireland’s ‘Young Entrepreneur of the Year’ in 2014 for establishing Nutriband. He has worked as a Business Mentor with 100 Minds, a social enterprise that brings together some of Ireland’s top college students and connects them with a cause to achieve large charitable goals. He received a B.Sc. in Business and Management from Dublin Institute of Technology.

Serguei Melnik is Co-Founder and President of Nutriband. He has been involved in general business consulting for companies in the U.S. financial markets and setting up legal and financial frameworks for operations of foreign companies in the U.S. He previously was the COO of Florida-based Asconi Corporation. He also was a lawyer in the Department of Foreign Affairs, JSC Bank “Inteprinzbanca,” in Chisinau, Moldova, and prior to that practiced law in Moldova. He is fluent in four languages.

Jeff Patrick, Pharm.D., is Chief Scientific Officer of Nutriband. He currently serves as Director of the Drug Development Institute at the Ohio State University Comprehensive Cancer Center. His prior roles included Global Vice President at Mallinckrodt Pharmaceuticals Inc.; and roles at Dyax, Myogen/Gilead, Actelion and Sanofi-Synthelabo Inc. He was a clinical pharmacist at the University of Tennessee Medical Center and a clinical assistant professor of pharmacy at the University of Tennessee College of Pharmacy.

Gerald Goodman is CFO of Nutriband. He is a certified public accountant with his own firm, Gerald Goodman CPA. He also practiced with Madsen & Associates, CPAs, and was a partner in the accounting firm of Wiener, Goodman & Company. He is also a director of Lifestyle Medical Network Inc., which provides management services to healthcare providers. He is a graduate of Pennsylvania State University, where he received a bachelor’s degree in accounting.

Nutriband Inc. (NASDAQ: NTRB), closed Tuesday's trading session at $4.275, up 4.0146%, on 21,246 volume. The average volume for the last 3 months is 15,054 and the stock's 52-week low/high is $3.96/$11.6779.

Recent News

• Nutriband Inc. (NASDAQ: NTRB) - BioMedNewsBreaks - Nutriband Inc. (NASDAQ: NTRB) Signs Exclusive Costa Rica Distribution Deal for AVERSA Fentanyl and Sports Tape Products
• BioMedNewsBreaks - Nutriband Inc. (NASDAQ: NTRB) (NASDAQ: NTRBW) Highlights Board Appointments and AVERSA Fentanyl Milestones From Annual Meeting
• InvestorNewsBreaks - Nutriband Inc. (NASDAQ: NTRB) Sells 90% Stake in Pocono Pharmaceutical for $5 Million

Canamera Energy Metals Corp. (CSE: EMET) (OTCQB: EMETF)

Disseminated on behalf of Canamera Energy Metals Corp., may include paid advertisements.

The QualityStocks Daily Newsletter would like to spotlight Canamera Energy Metals Corp. (CSE: EMET) (OTCQB: EMETF).

This article has been disseminated on behalf of Canamera Energy Metals Corp. and may include paid advertising.

Canamera Energy Metals (CSE: EMET) (OTCQB: EMETF) (FSE: 4LF0) announced it has entered into an option agreement with Gallik Explorations Inc. to earn up to a 100% interest in the 2,300-hectare Waterslide Property located approximately 20 km southeast of Bancroft, Ontario, subject to Canadian Securities Exchange approval. The property hosts seven documented uranium, thorium, fluorite and rare earth occurrences within the Central Gneiss Belt of the Grenville Province, and Canamera may secure full ownership through four staged cash and share payments totaling $200,000 over three years, after which the project will carry a 2% net smelter return royalty with a 1% buyback option for $1 million.

To view the full press release, visit https://ibn.fm/nqDp6

Canamera Energy Metals Corp. (CSE: EMET) (OTCQB: EMETF) is a rare earth and critical metals exploration company focused on developing a diversified portfolio of district-scale opportunities across the Americas. The company targets jurisdictions with supportive regulatory frameworks, strong geological signatures, and increasing strategic relevance as global supply chains seek alternatives to China’s rare earth dominance. Its assets span ionic clay systems in Brazil, carbonatite complexes in the United States and Canada, and underexplored terrains with meaningful geophysical and geochemical indicators.

Guided by a vision to support North American and allied rare earth supply chains, Canamera concentrates on high-conviction targets where early entry, scalable land positions, and efficient exploration can potentially unlock long-term value. The company’s mission is centered on generating discoveries aligned with the accelerating global demand for critical minerals essential to defense, advanced manufacturing, clean energy technology, and next-generation electronics. Through systematic data-driven exploration, Canamera aims to advance projects aligned with growing efforts to diversify rare earth supply across strategic jurisdictions.

The company is headquartered in Edmonton, Alberta.

Projects

Turvolândia – Minas Gerais, Brazil

Canamera holds an option to acquire up to a 100% ownership interest in the Turvolândia Rare Earth Ionic Clay Project, a 29,574-hectare land package located in Minas Gerais, Brazil’s top mining state and a region responsible for over 30% of national mineral output. The project sits within a prolific corridor of REE-rich alkaline rocks associated with the Poços de Caldas Complex, currently being advanced by multiple industry developers.

Turvolândia benefits from year-round road access, established infrastructure, and supportive local communities. The geological setting includes the São Vicente and Pouso Alegre complexes, where heavily weathered horizons host REE-enriched clays and minerals such as monazite and bastnäsite.

Early exploration confirms REE-bearing clays, with upcoming work focused on property-wide soil sampling and deeper drilling to test the primary ionic clay enrichment horizon and depth potential.

São Sepé – Rio Grande do Sul, Brazil

Canamera also holds an option to acquire up to a 100% interest in the São Sepé Project, which comprises 7,966 hectares in a province known for significant mining activity, including coal, gems, and titanium, and offers strong infrastructure and accessibility. The geology is dominated by an 11-km Rapakivi granite body and advanced-weathered granitoid rocks prospective for potential ionic clay REE mineralization.

While currently undrilled, initial soil sampling indicates the presence of REE enrichment potential. Three priority targets—Erica, Sara, and Maya—have been identified, with planned work including systematic soil sampling and drilling across defined zones. The project also covers a notable uranium-potassium-thorium anomaly, further supporting its rare earth potential.

Iron Hills – Colorado, USA

The Iron Hills Project consists of 85 unpatented lode claims totaling 1,756 acres, held at 100% ownership and located within the Iron Hills / Powderhorn carbonatite complex, one of the premier carbonatite-alkaline systems in the United States. Adjacent to Teck Resources’ Iron Hill deposit, host to one of the country’s largest rare earth oxide and titanium deposits, the project spans two non-contiguous claim blocks positioned along mapped intrusive contacts, felsite porphyry boundaries, and carbonatite dike projections.

Canamera staked these claims in 2025 as part of its U.S. expansion strategy supported by Rangefront Mining Services, and they are pending approval by the BLM.

Schryburt Lake – Ontario, Canada

Through a Joint Venture Option Agreement, Canamera may earn up to a 90% interest in the Schryburt Lake Project, a multi-center carbonatite-hosted REE–Nb system defined by four priority targets: Blue Jay, Goldfinch, Blackbird, and Starling.

These prospects exhibit coincident thorium radiometric highs, coherent magnetic bodies, surface anomalies, and historical trenching. Together, they outline the potential for a vertically extensive and multi-center REE–Nb system. Planned work includes a ~1,000-meter heli-supported scout drilling program following permitting and community consultation.

Garrow – Ontario, Canada

The Garrow Project covers 2,182 hectares located 43 km north-northeast of North Bay and is accessible year-round with strong local infrastructure. Canamera holds an option to acquire a 100% interest in the property.

Regional geochemical datasets include 26 samples above 500 ppm REE across Ontario, and three of these high-value anomalies occur within the Garrow Township area, making it a compelling target for early-stage exploration, including property-wide soil sampling and geophysics to delineate initial drill targets.

Market Opportunity

Rare earth elements play a central role in high-growth industries including electric vehicles, wind turbines, robotics, high-performance electronics, defense systems, and medical imaging, underpinning global trends in electrification, automation, and advanced manufacturing. Their application in permanent magnets, optics and lasers, catalysts, and nuclear and medical technologies positions them as foundational materials for both industrial innovation and national security.

Global demand for rare earth elements is projected to triple—from 59,000 tonnes in 2022 to 176,000 tonnes by 2035—driven by rapid EV adoption and wind-power expansion, with supply expected to lag by up to 30%, according to McKinsey & Company. The global REE market, valued at $3.95 billion in 2024, is forecast to reach $6.3 billion by 2030 at a compound annual growth rate of approximately 8.6%, according to Grand View Research, reflecting a sustained and widening supply-demand imbalance that supports new project development.

China currently controls approximately 60% of global rare earth mining and about 90% of processing capacity, reinforcing persistent price volatility and supply-chain concentration that have been highlighted by historical export restrictions, environmental crackdowns, and geopolitical disruptions. In response, North American governments have accelerated initiatives to strengthen domestic critical-minerals supply chains, including $1 billion in U.S. Department of Energy funding opportunities and Canada’s C$1.5 billion Critical Minerals Infrastructure Fund. Together, these structural shortages, policy tailwinds, and long-term electrification trends underscore the strategic relevance of Canamera’s diversified rare earth portfolio across Brazil, the United States, and Canada.

Leadership Team

Brad Brodeur, CEO & Director, brings more than 27 years of capital markets experience focused on venture-stage issuers, having led over $100 million in financings for junior and start-up companies following senior advisory roles at Raymond James, Canaccord Genuity, and Edward Jones.

Warren Robb, VP Exploration, brings over 35 years of global mineral exploration experience across North America, China, Africa, and South America, including senior roles with Nexus Gold, WPC Resources (now Bluestar Gold), Roxgold, TTM Resources, Majestic Gold, and Trivalence Mining.

Jelena Veljovic, CFO, brings public-company financial reporting and accounting expertise through her work with Treewalk Consulting in Vancouver, supported by prior experience in taxation and private-company accounting at Focus LLP in Calgary.

All technical and scientific information disclosed herein was reviewed and approved by Warren Robb, P.Geo (British Columbia), Vice-President, Exploration, of the Company and a “Qualified Person” as defined by National Instrument 43-101.

For a discussion of the Company’s QA/QC and data verification processes and procedures, please see its most recently filed technical report, a copy of which is available under Canamera’s profile at www.sedarplus.ca.

Canamera Energy Metals Corp. (OTCQB: EMETF), closed Tuesday's trading session at $0.4729, up 0.1164391%, on 134,345 volume. The average volume for the last 3 months is 310,400 and the stock's 52-week low/high is $0.279/$0.94.

Recent News

• Canamera Energy Metals Corp. (CSE: EMET) (OTCQB: EMETF) - RockBreaks - Canamera Energy Metals Corp. (CSE: EMET) (OTCQB: EMETF) (FSE: 4LF0) Options Waterslide Uranium and Rare Earth Project in Ontario
• MiningNewsBreaks - Canamera Energy Metals Corp. (CSE: EMET) (OTCQB: EMETF) (FSE: 4LF0) Engages Dr. Reuter Resources for Investor Relations Services
• Canamera Energy Metals Corp. (CSE: EMET) (OTCQB: EMETF) Builds Diversified Rare Earth Portfolio Across the Americas, Targeting Strategic Supply Security

Nevada Organic Phosphate Inc. (CSE: NOP) (OTCQB: NOPFF)

Disseminated on behalf of Nevada Organic Phosphate Inc., may include paid advertisements.

The QualityStocks Daily Newsletter would like to spotlight Nevada Organic Phosphate Inc. (CSE: NOP) (OTCQB: NOPFF).

Disseminated on behalf of Nevada Organic Phosphate Inc. (CSE: NOP) (OTCQB: NOPFF) and may include paid advertising.

Early drilling at Murdock Mountain project in Nevada shows an average grade of 10.93% P₂O₅ in the Upper Phosphatic Zone, alongside calcium, magnesium, silicon, and trace micronutrients.

Heavy metals such as cadmium, arsenic, and lead were reported well below common organic certification thresholds.

Management says the chemistry supports slow-release phosphorus and soil conditioning benefits.

The company is positioning Murdock Mountain as a potential direct-ship organic phosphate input rather than a conventional chemical fertilizer feedstock.

Nevada Organic Phosphate aims to advance the project amid rising demand for domestic, low-contaminant fertilizer sources.

Nevada Organic Phosphate (CSE: NOP) (OTCQB: NOPFF) , a B.C.-based leader in organic sedimentary phosphate exploration, announced that new assay interpretations from its Murdock Mountain property indicate the material could function as a naturally balanced, multi-nutrient mineral fertilizer aligned with organic and regenerative farming practices ( https://ibn.fm/oTvGI ).

Nevada Organic Phosphate Inc. (CSE: NOP) (OTCQB: NOPFF) is a junior exploration company focused on exploring and advancing an organic sedimentary raw rock phosphate project in northeast Nevada. The company’s business model centers on developing a rare, direct-application phosphate product that aligns with the growing demand for organic agricultural inputs. Its vision is to support the rapidly expanding organic food industry with a clean, reactive, environmentally responsible nutrient source that avoids the contamination issues associated with chemically processed fertilizers.

NOP is advancing the Murdock Mountain Project through disciplined exploration, responsible environmental practices, and strategic planning that positions the company as a future supplier of organic phosphate to key agricultural markets. The company emphasizes transparency, environmental stewardship, and adherence to regulatory standards as it advances its drill program and project development.

By developing a unique phosphate resource in a mining-friendly U.S. jurisdiction with strong infrastructure access, NOP aims to establish itself as a significant participant in the organic fertilizer sector.

The company is headquartered in Vancouver, British Columbia.

The Murdock Mountain Phosphate Project

NOP’s flagship asset is the Murdock Mountain Phosphate Project in Elko County, Nevada, a nearly flat-lying sediment-hosted phosphate system traced historically over 6.6 kilometers and extended through additional applications to more than 30 kilometers. The project’s raw rock phosphate is characterized by high purity, absence of heavy metals, and suitability for direct application without processing, aided by francolite (the most reactive crystallite structure of all P₂O₅ minerals) and oolitic textures that provide optimal surface area for interaction with soil micro-organisms. The product’s purity places it within the rare 5% of global P₂O₅ material pure enough for direct field application.

The Murdock Mountain property spans four Bureau of Land Management (BLM) applications totaling 7,824 acres, with an Exploration Target Mineral Inventory (ETMI) of 10–46 million tonnes in the initial 1,813-acre area and an additional 200–220 million tonnes across three further applications. Historic geologic mapping and recent drilling identify the Upper Phosphatic Zone within the Meade Peak Member as the primary target, with an interval historically ranging from 3.4 to 7.6 meters thick within a 28–40-meter phosphatic sequence.

In 2025, NOP commenced a multi-hole drill program with unrestricted seasonal timing following regulatory updates. Drill holes MM25-1, MM25-2, MM25-3, MM25-4 and MM25-5 all intersected favorable Meade Peak phosphate-bearing stratigraphy precisely where predicted by geological modeling. These intersections ranged from 29.2 to 38 meters (96 to 125 feet), with drilling confirming the interpreted dip and continuity of the target zone. Ongoing step-out drilling continues along the phosphate trend, supported by geological mapping and XRF screening, with assays pending. The project benefits from proximity to Highway SR 30, the hamlet of Montello, and the Southern Pacific rail line, enabling a simple mining concept summarized by: “break it up, dig it up, grind it up, bag it up, and ship it out.”

Market Opportunity

NOP intends to supply organic, direct-application phosphate fertilizer to the rapidly expanding organic food sector in North America. The company cites a $35 billion organic food market, supported by data from the U.S. Department of Agriculture’s Economic Research Service, which estimated an 8.7% annual growth rate between 2021 and 2027.

The shift toward organic and regenerative agriculture is driving demand for reactive, non-acidulated phosphate sources, and NOP notes that American farming practices are increasingly moving toward direct-application phosphate rather than soluble chemical fertilizers. With only 5% of global P₂O₅ pure enough for direct application, the company is targeting a rare, high-value segment of the fertilizer market that does not require competition with conventional chemical fertilizer producers.

Leadership Team

Robin Dow, Chairman & CEO, brings extensive experience as a public venture capital entrepreneur, following prior roles as a retail and institutional broker and researcher at Burns Fry. He has created more than 30 private and public companies across multiple sectors, raised close to $200 million, and built resource operations spanning four continents, 10 countries, four U.S. States, four Canadian provinces, and three Canadian territories.

Eric Szustak, Director, offers over 39 years of financial services, accounting, business development, and marketing experience, supported by senior roles at firms including Midland Walwyn, Merrill Lynch, and BMO Nesbitt Burns. He is the former President and current Chairman of Quinsam Capital Corporation and holds multiple directorships in publicly listed companies.

Garry K. Smith, Director, contributes more than 40 years of exploration management for companies such as Kerr Addison, Teck, Rio Tinto, and Lac Minerals. As a Qualified Person, he specializes in project generation, 43-101 reporting, resource evaluation, geological modeling, and metal ion soil geochemistry, with a strong focus on ethical and environmentally responsible exploration practices.

Paul W. Pitman, P.Geo., Director, is a field hardened veteran with extensive experience in all areas of geological exploration for a number of metals and materials. He has over 55 years’ experience as an exploration geologist. Since 1983, he has acted as a geological consultant to over 70 clients, providing a full range of services (geological, corporate, and administrative). He has served as a Director or Officer (VP or President) of several junior resource companies, including Boreal Agrominerals, a producer off organic fertilizers from igneous rock in Northern Ontario. He is semi-retired but directs his geological expertise as an advisor to several fertilizer companies.

Nevada Organic Phosphate Inc. (OTCQB: NOPFF), closed Tuesday's trading session at $0.116, up 22.4921%, on 89,080 volume. The average volume for the last 3 months is 638,460 and the stock's 52-week low/high is $0.0334/$0.3212.

Recent News

• Nevada Organic Phosphate Inc. (CSE: NOP) (OTCQB: NOPFF) - Nevada Organic Phosphate Inc. (CSE: NOP) (OTCQB: NOPFF) Assay Results Reveal Multi-Nutrient Phosphate Profile Suited to Organic and Regenerative Agriculture
• RockBreaks - Nevada Organic Phosphate Inc. (CSE: NOP) (OTCQB: NOPFF) to Present Live Virtual Corporate Update Feb. 17
• RockBreaks - Nevada Organic Phosphate Inc. (CSE: NOP; OTCQB: NOPFF) Reports Initial Assay Results from Murdock Mountain Property in Nevada

Earth Science Tech Inc. (OTC: ETST)

The QualityStocks Daily Newsletter would like to spotlight Earth Science Tech Inc. (OTC: ETST).

Earth Science Tech (OTC: ETST) was featured on the latest episode of The BioMedWire Podcast released by IBN, with Chairman and CEO Giorgio R. Saumat outlining the company's vertically integrated healthcare model spanning telehealth and compounding pharmaceuticals, its cash-flow-positive operations and strong balance sheet, and preparations for a potential uplist. During the interview, Saumat highlighted the company's profitability, limited debt and 2025 diversification initiatives, as Earth Science Tech positions to scale operations in 2026 while IBN continues expanding its specialized content distribution platform.

To view the full press release, visit https://ibn.fm/iSd01

Earth Science Tech (OTC: ETST) reported financial and operational results for the third fiscal quarter ended Dec. 31, 2025, with revenue of $8.4 million, up 14.1% year over year, gross profit of $6.4 million reflecting a 76.3% margin, and net income of $910,000, up 341% from the prior-year period. Adjusted EBITDA totaled $1.2 million, total assets increased to $8.1 million, and the company repurchased and retired 3.7 million shares during the first nine months of fiscal 2026, while ending the quarter with $416,000 in cash, $773,000 in working capital and no bank debt as management cited continued operating leverage and expansion initiatives heading into calendar 2026.

To view the full press release, visit https://ibn.fm/emIBm

Earth Science Tech (OTC: ETST) announced it has engaged Semple, Marchal & Cooper LLP as its new independent Public Company Accounting Oversight Board auditor, citing the need to strengthen its financial governance framework as operations expand across pharmacy compounding, telemedicine and real estate. The board determined that the firm's broader resources and multidisciplinary expertise align with the company's growing operational complexity, supporting enhanced auditing efficiencies and oversight as ETST continues scaling its diversified health and wellness portfolio.

To view the full press release, visit https://ibn.fm/hEaGE

Earth Science Tech (OTC: ETST) announced a series of strategic initiatives aimed at enhancing transparency, governance and alignment with long-term shareholder value as it advances toward becoming a fully institutional-ready public company. Building on approximately $3.3 million in net income for fiscal 2025 and anticipated $1.4 million in cost savings in fiscal 2026, the company outlined plans to optimize its portfolio through potential divestitures and brand consolidation, introduce advisory shareholder votes on executive compensation and Series B Preferred Stock retirement, rationalize its capital structure and reduce executive and board compensation, as management positions the company for disciplined growth and improved operating leverage.

To view the full press release, visit https://ibn.fm/pNJIc

Earth Science Tech Inc. (OTC: ETST) is a strategic holding company that builds value by acquiring and actively managing operating businesses in pharmaceuticals, telemedicine, healthcare services, real estate, and select consumer markets. The company focuses on controlling interests in subsidiaries where operational oversight, regulatory compliance, and disciplined scaling can drive durable growth.

Since 2022, Earth Science Tech has completed a deliberate transition away from legacy activities and repositioned the organization around healthcare and pharmaceutical operations. That shift has been supported by regulatory alignment, expanding operating capabilities, and the assembly of a diversified portfolio of revenue-generating businesses.

Today, the company’s approach emphasizes execution, capital discipline, and long-term value creation across its operating platforms, with a focus on scaling businesses that can grow sustainably while enhancing shareholder value.

The company is headquartered in Miami, Florida.

Subsidiaries

Earth Science Tech conducts its operations through a portfolio of wholly owned and majority-owned subsidiaries spanning pharmaceutical compounding, telemedicine, healthcare services, real estate development, and direct-to-consumer products.

• RxCompoundStore.com LLC – A fully licensed compounding pharmacy based in Miami, Florida, authorized to fulfill prescriptions across more than 20 U.S. states and Puerto Rico, with ongoing licensure expansion efforts nationwide.
• Mister Meds LLC – A Texas-based compounding pharmacy operating from a 5,000-square-foot facility with advanced sterile and hazardous drug compounding capabilities, acquired to expand production capacity and geographic reach.
• Peaks Curative LLC – A telemedicine referral platform providing asynchronous consultations for Peaks-branded compounded medications, supported by an expanding provider network and recent entry into the veterinary market through Zoolzy.com.
• DOConsultations LLC – An online telehealth platform focused on customized medication formulations, supporting direct-to-patient delivery through partner pharmacies.
• Las Villas Health Care Inc. – A brick-and-mortar and telehealth healthcare provider serving the Spanish-speaking community, offering specialized wellness and sexual health services.
• Avenvi LLC – A diversified real estate development and asset management company overseeing property investments, development projects, and the company’s ongoing share repurchase program.
• MagneChef (80% interest) – A direct-to-consumer retail brand leveraging proprietary intellectual property to develop and market kitchen and cooking-related products, with recent expansion into premium American-made BBQ tools.
• Earth Science Foundation Inc. – A 501(c)(3) nonprofit organization serving as the company’s charitable arm, providing financial assistance for prescription costs to qualified individuals.

Collectively, these subsidiaries provide Earth Science Tech with diversified exposure across regulated healthcare services, digital health platforms, real estate assets, and proprietary consumer brands.

Market Opportunity

Earth Science Tech is primarily positioned within the pharmaceutical compounding and telemedicine markets, both of which are experiencing sustained growth driven by demand for personalized healthcare solutions, expanded access to care, and increasing adoption of remote service models.

The pharmaceutical compounding market continues to benefit from rising demand for customized medications, improved patient adherence, and supply-chain flexibility. According to Grand View Research, the global compounding pharmacies market was valued at approximately $13.1 billion in 2023 and is projected to reach $18.6 billion by 2030, representing a compound annual growth rate of 5.11% from 2024 to 2030. Earth Science Tech’s compounding operations through RxCompoundStore.com and Mister Meds align directly with this expanding market segment.

Telemedicine represents a second core growth vertical for the company, supporting the clinical delivery of pharmaceutical products and healthcare services. According to Fortune Business Insights, the global telemedicine market was valued at $111.99 billion in 2025 and is projected to grow to $532.08 billion by 2034, reflecting a compound annual growth rate of 20.0%, with North America accounting for approximately 48% of market share in 2025. Platforms operated by Peaks Curative and DOConsultations participate directly in this rapidly expanding digital health ecosystem.

Additional exposure to specialty healthcare clinics and real estate development provides diversification alongside the company’s core pharmaceutical and telemedicine operations.

Leadership Team

Giorgio R. Saumat, Chief Executive Officer and Chairman of the Board, is an investor and entrepreneur with more than 20 years of experience investing in, operating, and advising private businesses, including founding CASAU Group, a private equity firm focused on real estate, and POINT96 Consulting, which provides strategic planning services to businesses and accredited investors.

Ernesto L. Flores, Chief Financial Officer, is a financial executive with over a decade of experience in accounting, taxation, and financial management, having held senior roles overseeing compliance and financial operations at logistics and investment firms.

Mario G. Tabraue, President and Chief Operating Officer, brings experience across real estate, maritime operations, and digital infrastructure and was instrumental in acquiring RxCompoundStore.com with the vision of scaling it into a nationally competitive pharmaceutical and telemedicine platform.

Christopher Rose, Chief Technology Officer, is a technology and automation executive who previously led enterprise-wide automation initiatives at a Fortune 100 company, delivering large-scale operational efficiencies and global process automation.

Earth Science Tech Inc. (OTC: ETST), closed Tuesday's trading session at $0.13, even for the day, on 50,130 volume. The average volume for the last 3 months is 125,510 and the stock's 52-week low/high is $0.001/$0.237.

Recent News

• Earth Science Tech Inc. (OTC: ETST) - BioMedNewsBreaks - Earth Science Tech, Inc. (OTC: ETST) Reports Fiscal Q3 2026 Revenue Up 14% and Net Income Up 341%
• BioMedNewsBreaks - Earth Science Tech, Inc. (OTC: ETST) Featured on Latest BioMedWire Podcast by IBN
• BioMedNewsBreaks - Earth Science Tech, Inc. (OTC: ETST) Announces Governance and Capital Structure Initiatives to Advance Institutional Readiness

NRx Pharmaceuticals Inc. (NASDAQ: NRXP)

The QualityStocks Daily Newsletter would like to spotlight NRx Pharmaceuticals Inc. (NASDAQ: NRXP).

NRx Pharmaceuticals (NASDAQ: NRXP) announced completion of an in-person Type C guidance meeting with the U.S. Food and Drug Administration, attended by leadership from the Division of Psychiatry Products, Office of Neuroscience and Center for Drug Evaluation and Research. Based on oral guidance, the company believes it has a path to file a New Drug Application for NRX-100, a preservative-free ketamine formulation, supported by existing adequate and well-controlled trials and confirmatory evidence from more than 65,000 patients in a Real World Evidence dataset, while also seeking a broader indication for treatment-resistant depression with suicidality. The FDA advised that no additional nonclinical or bridging studies would be required, and the company said it will work with the agency to finalize a statistical analysis protocol, with further details to follow upon receipt of formal meeting minutes.

To view the full press release, visit https://ibn.fm/fC2ec

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders, with a particular emphasis on conditions characterized by acute suicidality. The company is leveraging its proprietary NMDA receptor modulation platform to address significant unmet medical needs in suicidal depression, bipolar depression, chronic pain, and post-traumatic stress disorder (PTSD).

With a commitment to advancing life-saving treatments, NRx is developing novel therapeutics aimed at providing safer and more effective alternatives to current treatment options. Its lead investigational drug, NRX-101, is positioned to be the first FDA-approved oral therapy for suicidal bipolar depression. Additionally, the company is working to bring NRX-100 (intravenous ketamine) to market as an approved treatment for acute suicidal depression, a condition for which existing treatments remain limited.

By integrating cutting-edge science with a patient-focused mission, NRx aims to transform the standard of care for individuals suffering from severe psychiatric and neurological conditions.

NRx has also established HOPE Therapeutics, a subsidiary focused on delivering interventional psychiatric care through a nationwide clinic network. HOPE Therapeutics aims to become the first coordinated system of care for suicidal depression and PTSD, combining ketamine, Transcranial Magnetic Stimulation (TMS), digital therapeutics, and other precision psychiatry tools in a supervised clinical environment.

NRx is headquartered in Wilmington, Delaware. HOPE is headquartered in Miami, Florida.

Product Portfolio

NRx Pharmaceuticals’ pipeline includes multiple late-stage therapeutic candidates targeting psychiatric and neurological disorders:

• NRX-100: A preservative free intravenous ketamine formulation under development for acute suicidal depression, backed by strong clinical trial data and Fast Track designation from the FDA.
• NRX-101: An oral therapy with a dual mechanism targeting NMDA and 5-HT2A receptors, designed for patients with suicidal treatment-resistant bipolar depression. The drug has received Breakthrough Therapy designation from the FDA.
• Expanded Research: The company is further evaluating NRX-101 as a potential non-opioid treatment for chronic pain and a therapy for complicated urinary tract infections.

NRx’s therapeutic pipeline is designed to address conditions with limited or no treatment options, with the potential to improve patient outcomes and expand the standard of care.

HOPE Therapeutics

HOPE Therapeutics, a wholly owned subsidiary of NRx Pharmaceuticals, is establishing a national network of psychiatrist-led clinics focused on suicidal depression and PTSD. Its care model integrates preservative-free ketamine, TMS, digital therapeutics, and supervised psychiatric support to deliver rapid, measurable outcomes.

The company is targeting more than 30 clinic acquisitions by year-end 2025. Recent agreements include the acquisition of Dura Medical and a letter of intent with Neurospa TMS, strengthening HOPE’s foundation in interventional psychiatry. In April, HOPE also secured a term sheet for strategic investment from a global medical device manufacturer.

With ketamine sales already underway under a 503B license, HOPE projects $100 million in annual revenue and profitability by year-end 2025. Positioned as a standalone care delivery company, HOPE offers NRx a potential future spinout opportunity to unlock additional shareholder value.

Market Opportunity

The need for innovative treatments in mental health and pain management is substantial. Suicide is a leading cause of death in the United States, claiming nearly 50,000 lives each year, with over 12 million adults seriously considering suicide annually, according to the CDC.

Suicidal depression, a distinct and life-threatening condition, affects approximately 3.5 million Americans. Despite this prevalence, the only approved intervention remains electroconvulsive therapy (ECT), a treatment with significant side effects and limited access. NRx aims to address this urgent gap with NRX-100, a preservative-free intravenous ketamine formulation being developed as the first FDA-approved treatment specifically for suicidal depression.

Additionally, approximately 7 million Americans suffer from bipolar depression, a condition where nearly half of patients will attempt suicide during their lifetime and one in five may die by suicide. NRX-101, NRx’s oral drug candidate, targets this critical unmet need as a potential first-in-class therapy specifically for bipolar depression.

Beyond mood disorders, chronic pain affects over 50 million individuals in the U.S., and PTSD impacts more than 12 million people—conditions for which few non-opioid, fast-acting treatments are available. By addressing these high-risk, underserved populations, NRx Pharmaceuticals is positioned to enter multiple billion-dollar markets and reshape the standard of care for severe psychiatric and neurological illnesses.

Leadership Team

Jonathan C. Javitt, Founder, Chairman & Chief Executive Officer or NRx, and Co-CEO of HOPE, brings four decades of experience in pharmaceutical and medical device development. He has led blockbuster drug and device programs at major companies, including Allergan, Merck, and Novartis, and has served as an advisor to four U.S. presidential administrations.

Michael Abrams, Chief Financial Officer, has nearly 30 years of experience in finance, having served in executive roles, including CFO positions at Arch Therapeutics and FitLife Brands. His expertise spans investment banking, corporate finance, and business strategy.

Rick Panicucci, Chief Technology Officer, has more than 25 years of leadership in pharmaceutical manufacturing and process development. He has held key positions at Novartis, WuXi AppTec, and other major companies, leading multiple approved New Drug Applications.

Matthew Duffy, Chief Business Officer, NRx, Co-CEO of HOPE, has over 35 years of experience in biotechnology business development and investment banking. He has held leadership roles at Pfizer, MedImmune, and several financial institutions, specializing in corporate strategy and partnerships.

NRx Pharmaceuticals Inc. (NASDAQ: NRXP), closed Tuesday's trading session at $1.8, even for the day, on 478,162 volume. The average volume for the last 3 months is 1,506,516 and the stock's 52-week low/high is $1.58/$3.84.

Recent News

• NRx Pharmaceuticals Inc. (NASDAQ: NRXP) - BioMedNewsBreaks - NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Completes FDA Type C Meeting for NRX-100 NDA Pathway
• PsychedelicNewsBreaks - NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Licenses Real-World Evidence From 70,000 Patients to Support FDA Accelerated Approval of NRX-100
• BioMedNewsBreaks - NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Partners With neurocare Group AG To Build Nationwide Neuroplastic Care Network

Forward Industries Inc. (NASDAQ: FWDI)

The QualityStocks Daily Newsletter would like to spotlight Forward Industries Inc. (NASDAQ: FWDI).

The first quarter of fiscal 2026 was an important milestone for the company, as it represents the first full reporting period that FWDI operates as the worlds largest Solana (SOL) treasury company.

The company announced information about treasury holdings, staking performance, financial results, and more.

FWDI also mentioned several milestones and accomplishments the company has reached, and the goals for the future.

Forward Industries (NASDAQ: FWDI) , a SOL treasury company, recently reported the company's fiscal first quarter 2026 financial and operating results

Forward Industries Inc. (NASDAQ: FWDI) is building and managing a large-scale Solana (SOL) treasury, backed by some of the most influential investors in the digital asset space. The company’s strategy centers on long-term shareholder value through active participation in the Solana ecosystem, which it views as uniquely positioned to underpin future global capital markets due to its high throughput, deep economic activity, and growing developer adoption.

Through this shift, Forward Industries aims to create value by accumulating SOL and strategically deploying assets through on-chain opportunities including staking, lending, and participation in decentralized finance (DeFi). Forward also became the first U.S.-listed company to bring its common stock onto the Solana blockchain, reinforcing its focus on digital-native capital markets.

Forward Industries is headquartered in New York.

Solana Treasury Operations

In September 2025, Forward Industries closed a $1.65 billion private investment in public equity (PIPE) led by Multicoin Capital, Galaxy Digital, and Jump Crypto. The PIPE proceeds were deployed to acquire over 6.8 million SOL at an average price of $232 per token, with a portion executed on-chain via DFlow, a decentralized exchange aggregator built exclusively for Solana trading applications. The company has since staked the entirety of its treasury, actively generating yield through native Solana infrastructure and DeFi applications.

Forward’s strategy is centered on growing SOL per share, leveraging a range of tools including at-the-market (ATM) equity offerings and potential preferred equity issuance. The company is also targeting acquisitions and strategic partnerships within the Solana ecosystem to accelerate treasury yield and ecosystem alignment. As part of its infrastructure expansion, Forward tokenized its FORD shares on the Solana blockchain in collaboration with Superstate and plans to acquire an equity interest in the platform. The tokenized shares are expected to enable 24/7 trading, real-time settlement, and eligibility for use as DeFi collateral.

This shift was supported by the company’s board and executive team, whose composition reflects deep alignment with the Solana ecosystem — including leadership from Multicoin Capital and board observers from Galaxy and Jump Crypto. The company’s stated objective is to establish itself as the leading institutional participant in the Solana ecosystem, uniquely positioned to capture both economic yield and strategic exposure to one of the fastest-growing blockchain networks in the world.

Market Opportunity

Solana has emerged as the most performant blockchain in the digital asset space, processing over 8.9 billion transactions in Q2 2025 and sustaining approximately $3 billion in daily decentralized exchange (DEX) trading volume. Year to date, Solana applications have generated over $4 billion in fees and more than $1 billion in real economic value (REV), a proxy for free cash flow generated by the network.

DeFi participation, stablecoin usage, and developer activity have all grown substantially, with over $1.5 trillion in swap volume recorded through 2025. SOL staking yields have averaged over 8%, comprised of both inflationary rewards and organic yield from network activity. With 17 pending ETF applications and major institutions like BlackRock, Visa, PayPal, and HSBC integrating Solana, Forward Industries is positioned to benefit from a rising tide of institutional adoption, tokenization of real-world assets, and increased demand for high-performance blockchain infrastructure.

Leadership Team

Kyle Samani, Chairman of Forward Industries, is the co-founder and Managing Partner of Multicoin Capital, an early Solana backer and one of the largest holders of SOL. Samani contributed $25 million to the PIPE and is a key strategic leader behind Forward’s treasury roadmap.

Mike Pruitt, Interim CEO of Forward Industries, joined the board in February 2025 and was appointed Interim CEO in May. He is the founder of Avenel Financial Group and previously served as CEO of Chanticleer Holdings, bringing decades of public company leadership and capital markets experience.

Kathleen Weisberg, Chief Financial Officer of Forward Industries, was appointed CFO in July 2023 after serving as Corporate Controller since 2020. Weisberg is a CPA with prior roles at WW International, Symbol Technologies, and Ernst & Young.

Forward Industries Inc. (NASDAQ: FWDI), closed Tuesday's trading session at $4.74, off by 1.8634%, on 594,564 volume. The average volume for the last 3 months is 899,729 and the stock's 52-week low/high is $3.32/$46.

Recent News

• Forward Industries Inc. (NASDAQ: FWDI) - Forward Industries Inc. (NASDAQ: FWDI) Announces Fiscal First Quarter 2026 Financial and Operational Results, and an Update on the SOL Treasury Strategy
• CryptoNewsBreaks - Forward Industries, Inc. (NASDAQ: FWDI) Reports Q1 Fiscal 2026 Results, Details SOL Treasury Expansion
• MissionIRNewsBreaks - Forward Industries, Inc. (NASDAQ: FWDI) to Host Conference Call on First-Quarter 2026 Results Feb. 12

Trilogy Metals Inc. (NYSE American: TMQ) (TSX: TMQ)

The QualityStocks Daily Newsletter would like to spotlight Trilogy Metals Inc. (NYSE American: TMQ) (TSX: TMQ).

This article has been disseminated on behalf of Trilogy Metals Inc. and may include paid advertising.

Trilogy Metals (NYSE American: TMQ) (TSX: TMQ) reported financial results for the year ended Nov. 30, 2025, highlighting a cash balance of $51.6 million and a $17.8 million strategic investment commitment from the U.S. federal government in support of the Upper Kobuk Mineral Projects in Alaska, held through its 50/50 joint venture Ambler Metals LLC with South32 Limited. The company also approved a $35 million 2026 budget for Ambler Metals to advance permitting and development milestones, including potential mine permit submissions in 2026, as the Alaska Industrial Development and Export Authority executed Right-of-Way permits for the Ambler Access Project and the U.S. government signaled support in facilitating road construction financing, positioning the Arctic copper-silver-zinc-lead-gold deposit for further advancement.

To view the full press release, visit https://ibn.fm/CUJkp

Trilogy Metals Inc. (NYSE American: TMQ) (TSX: TMQ) is a North American mineral exploration and development company focused on advancing high-grade copper and critical mineral assets in Alaska. The company operates through Ambler Metals LLC, a 50/50 joint venture with South32 Ltd., and is progressing one of the world’s most prospective undeveloped polymetallic districts.

Trilogy is uniquely positioned with exposure to copper, zinc, lead, cobalt, silver, and gold—commodities vital to global electrification and energy transition. Its vision is to responsibly develop the Ambler Mining District into a premier domestic source of critical minerals while delivering long-term value to shareholders and local communities.

The company is guided by values of trust, respect, integrity, and partnership, and works closely with Alaska Native stakeholders to advance its strategy in a sustainable and inclusive manner.

Projects

Arctic Project

The Arctic project is Trilogy’s flagship asset and one of the highest-grade known copper deposits in the world, with an average grade of approximately 5% copper equivalent. Located roughly 470 kilometers northwest of Fairbanks, Alaska, Arctic is a volcanogenic massive sulphide (VMS) deposit hosting copper, zinc, lead, gold, and silver. The project is at the feasibility stage and is currently undergoing permitting activities.

According to the 2023 Feasibility Study, Arctic will support a 10,000 tonne-per-day open-pit mining operation over a 13-year mine life. Based on long-term metal prices of $3.65/lb copper, $1.15/lb zinc, $1.00/lb lead, $1,650/oz gold, and $21.00/oz silver, the project demonstrates a pre-tax NPV8% of $1.5 billion and an IRR of 25.8%. After-tax, the NPV8% is $1.1 billion with a 22.8% IRR. At April 2025 spot metal prices, the after-tax NPV8% increases to $1.9 billion with a 31.1% IRR.

The project’s metallurgy supports high recoveries: 92.1% for copper, 88.5% for zinc, and 61.3% for lead. Life-of-mine payable production is projected to total 1.9 billion pounds of copper, 2.2 billion pounds of zinc, 335 million pounds of lead, 423,000 ounces of gold, and 36 million ounces of silver. Cash costs are expected to average $0.72 per pound of payable copper, with all-in costs estimated at $1.61 per pound.

Bornite Project

Located approximately 25 kilometers southwest of Arctic, the Bornite project is a large-scale carbonate replacement copper deposit with significant upside. According to the 2025 Preliminary Economic Assessment (PEA), Bornite is expected to support a 6,000 tonne-per-day underground operation over a 17-year mine life, using re-purposed infrastructure from the Arctic Project.

Bornite contains an estimated 6.5 billion pounds of inferred copper. The PEA outlines pre-tax NPV8% of $552.1 million and IRR of 23.6%, with an after-tax NPV8% of $393.9 million and IRR of 20.0%, based on a copper price of $4.20/lb. Total payable copper production over the life of mine is projected at 1.9 billion pounds.

Bornite’s mineralization occurs in stacked, stratabound zones rich in chalcopyrite, bornite, and chalcocite. A subset of the South Reef zone offers high-grade underground mining potential, further enhancing Bornite’s future optionality.

Exploration Pipeline

The Upper Kobuk Mineral Projects span 471,796 acres and include more than 30 additional mineralized prospects beyond Arctic and Bornite. These lie along two geologically distinct and highly mineralized belts: the Ambler Schist Belt and the Bornite Carbonate Sequence.

The Ambler Schist Belt features multiple VMS-style prospects along its 100-kilometer strike length, including Sunshine, Snow, Nora, Shungnak, and BT. Neighboring deposits like Smucker (Teck) and Sun (Valhalla Metals) affirm the district’s regional potential. Ten of Trilogy’s VMS prospects have been drill tested with encouraging results.

Meanwhile, the Bornite Carbonate Sequence extends 16 kilometers along the Cosmos Hills and hosts additional targets such as Pardner Hill and Aurora Mountain. These zones show strong signs of copper and cobalt mineralization and were partially tested during the Kennecott era, suggesting significant room for expansion.

Together, these assets form the foundation of a multi-decade development and discovery platform in one of the most prospective undeveloped mining districts in North America.

Market Opportunity

Trilogy Metals is poised to benefit from long-term structural demand for copper and other critical minerals essential to electrification, energy infrastructure, and clean technologies. Copper, in particular, is expected to see major supply shortfalls due to underinvestment and accelerating demand from power grids, EVs, and data centers.

According to a Grand View Research report, the global copper market is projected to grow from $241.88 billion in 2024 to $339.95 billion by 2030, at a CAGR of 6.5%, driven by the energy transition and rising infrastructure investments.

Trilogy’s Arctic and Bornite projects are strategically located in Alaska, a top-tier mining jurisdiction with strong permitting frameworks and growing federal and state-level support, including recent executive orders streamlining approvals for the Ambler Access Project. The company also maintains a $50 million shelf prospectus and an active $25 million ATM equity program to fund future development.

Leadership Team

Tony Giardini, President and Chief Executive Officer, leads Trilogy Metals with extensive executive experience in the mining industry. He previously served as President of Ivanhoe Mines Ltd., and as Executive Vice President and Chief Financial Officer at Kinross Gold Corporation. Earlier in his career, he held senior roles at Placer Dome Inc. and KPMG. Mr. Giardini is both a Chartered Professional Accountant and a Certified Public Accountant.

Elaine M. Sanders, Chief Financial Officer and Corporate Secretary, brings over 25 years of financial and accounting experience to Trilogy. She is responsible for the company’s financial reporting, compliance, and governance functions. Ms. Sanders has overseen multiple financings and exchange listings throughout her career. She holds a Bachelor of Commerce from the University of Alberta and is both a Chartered Professional Accountant and Certified Public Accountant.

Richard Gosse, Vice President, Exploration, is a veteran geologist with 35 years of global exploration experience. He previously led exploration initiatives at Dundee Precious Metals and Ivanhoe Mines Ltd., where he oversaw the discovery efforts at the renowned Oyu Tolgoi copper-gold project in Mongolia. Mr. Gosse holds a B.Sc. in Geology from Queen’s University and an M.Sc. in Mineral Exploration from Imperial College London.

Trilogy Metals Inc. (NYSE American: TMQ), closed Tuesday's trading session at $3.69, off by 12.5592%, on 7,219,040 volume. The average volume for the last 3 months is 6,189,884 and the stock's 52-week low/high is $1.125/$11.29.

Recent News

• Trilogy Metals Inc. (NYSE American: TMQ) (TSX: TMQ) - BillionDollarBreaks - Trilogy Metals Inc. (NYSE American: TMQ) (TSX: TMQ) Reports Fiscal 2025 Results and Advances Upper Kobuk Projects
• RockBreaks - Trilogy Metals Inc. (NYSE American: TMQ) (TSX: TMQ) Positioned to Unlock Alaska's Mineral Resources
• Trilogy Metals Inc. (NYSE American: TMQ) (TSX: TMQ) Strengthens Position amid US Push to Secure Domestic Critical Mineral Supply

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The QualityStocks Daily Newsletter would like to spotlight CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

CNS Pharmaceuticals (NASDAQ: CNSP) announced that recently appointed President and CEO Rami Levin, in alignment with the board, has recruited Steven O'Loughlin as chief financial officer, Eric Faulkner as chief technology officer and Dylan Wenke as chief business officer, effective March 2, 2026. The company said the appointments support its strategic evolution following a comprehensive review of its pipeline and capital allocation priorities, positioning CNS Pharmaceuticals to advance development programs with a focus on disciplined growth, operational execution and long-term value creation in treatments for brain and central nervous system cancers.

To view the full press release, visit https://ibn.fm/lcSDZ

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (https://nnw.fm/eDUjp).

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Tuesday's trading session at $3.26, off by 5.7803%, on 16,096 volume. The average volume for the last 3 months is 66,348 and the stock's 52-week low/high is $3.09/$99.96.

Recent News

• CNS Pharmaceuticals Inc. (NASDAQ: CNSP) - TinyGemsBreaks - CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Appoints New Executive Leadership Team
• Groundbreaking Study Uncovers Why Breast Cancer Metastasizes to the Brain
• New AI Model Predicts Dementia Risk, Cancer Survival and Brain Age

Wearable Devices Ltd. (NASDAQ: WLDS)

The QualityStocks Daily Newsletter would like to spotlight Wearable Devices Ltd. (NASDAQ: WLDS).

The broader wearable technology market has been expanding rapidly as connectivity, health monitoring and intuitive user interfaces drive consumer and enterprise interest

The company's vision also anticipates broader adoption beyond gaming, healthcare or fitness applications

The global appetite for more intuitive, seamless interaction with technology is accelerating, and AI-powered, touchless sensing wearables are emerging as a cornerstone of this transformation. Wearable Devices (NASDAQ: WLDS) is at the forefront of this trend, leveraging neural-input interfaces and gesture recognition technology to provide hands-free control solutions that may redefine how users interact with consumer electronics and smart environments. Recent developments from the company highlight both growing market demand and Wearable Devices' strategic role in unlocking new use cases for touchless wearable technology.

Wearable Devices (NASDAQ: WLDS) announced the upcoming launch of Mudra Experience Studio, a developer platform designed to standardize neural gesture input across extended reality, mobile and AI-powered applications. The platform will offer production-ready SDKs, a unified gesture taxonomy and OEM integration tiers to enable cross-platform deployment without platform-specific rebuilding, positioning the company to expand from a hardware-focused innovator to a full-stack platform provider, while supporting its 2026 rollout through a priority waitlist and recent leadership expansion within its ai6 Labs division.

To view the full press release, visit https://ibn.fm/WHyvl

Wearable Devices Ltd. (NASDAQ: WLDS) is a growth-stage technology company pioneering the next generation of human-computer interaction through AI-powered neural input wearables. Mudra, its proprietary wrist-worn technology, enables touchless, gesture-based control of digital devices, offering users a seamless, intuitive interface through subtle finger and hand movements. Since introducing its technology to the market in 2014, the company has pursued both business-to-business (B2B) and business-to-consumer (B2C) strategies through a dual-channel model.

The company believes the future of technology should begin with the human. Wearable Devices envisions decoding the human body to enable context-aware AI-powered technology that listens, learns, and adapts – to us.

The company envisions a future where human intent becomes the language of technology. Through non-invasive neural sensing and adaptive algorithms, the company enables more natural, personalized, and intuitive interactions with computers.

The company is headquartered in Yokneam Illit, Israel.

Products

Neural control has entered the market: commercially available since 2023 with the Mudra Band and already used by thousands of users worldwide. With its product line, including Mudra Band and Mudra Link, the company has introduced the world’s first wrist-worn neural interfaces, enabling intuitive, touchless control through natural micro-gestures: subtle finger movements and wrist flicks. Whether streaming media, controlling smart devices, or interacting with AR glasses, Mudra brings neural input into everyday life.

This early adoption isn’t just validation — it’s acceleration. With real users engaging in real environments, the company is learning fast, improving faster, and shaping a product that grows more refined with every interaction.

Mudra Band

Mudra Band is the company’s flagship B2C product, designed as a sleek, aftermarket accessory for the Apple Watch. It uses patented sEMG sensors to detect neural signals from the wrist and translates them into real-time digital commands. This allows users to control and streamline interactions between the iPhone, iPad, MacBook, and Apple TV using familiar micro-gestures like taps, pinches, or swipes — all without touching a screen.

The device features a high-resolution analog front end, IMU integration, adaptive machine learning, and ergonomic form factors for all-day comfort. Users can toggle between multiple Apple devices using the Mudra Band’s dedicated Apple Watch face, enabling a fully connected, touchless experience. The Mudra Band is optimized for low-latency, high-accuracy interactions and supports a wide range of digital applications. The Mudra Band received a CES 2021 Innovation Award.

Mudra Link

Mudra Link expands the company’s reach beyond the Apple ecosystem, offering compatibility with Android, Windows, and AR/XR platforms. The product includes the innovative Gesture Mapper feature, allowing users to assign personalized commands to gestures such as tap, pinch, flick, or twist. This functionality replaces or augments traditional input methods, supporting media controls, pointer input, and full directional mapping. A key feature of Mudra Link is its dual-mode input system (mouse mode or D-pad mode), empowering users to personalize control schemes across devices, operating systems, and user interfaces.

Mudra Link is recognized for its ergonomic design, lightweight build, and plug-and-play ease of use. It supports native integration with AR glasses from leading manufacturers and received a CES 2025 Innovation Award.

Mudra DevKit and Integration

In parallel with its consumer devices, Wearable Devices offers a Mudra Developer Kit (MDK) and integration program for enterprise and OEM partners. The MDK includes full-stack tools (hardware bands, SDK, APIs, and sample code) that allow developers and original equipment manufacturers to embed Mudra’s neural sensing capabilities into their own products and applications. For example, an AR headset maker can integrate Mudra’s sensors to enable native hand-gesture input, or a software developer can use Mudra’s API to track user gestures for novel interactions.

The MDK supports both Android and iOS and even provides real-time neural raw signal monitoring for research and prototyping. This B2B offering not only expands Mudra technology into new environments such as industrial automation, robotics, and gaming peripherals, but also fosters a broader ecosystem of Mudra-powered solutions. By lowering the barrier for others to adopt its AI gesture recognition engine, Wearable Devices accelerates innovation and garners strategic relationships.

The MDK and related licensing offerings illustrate Wearable Devices’ push-pull strategy: selling consumer products today, while seeding ‘Mudra inside’ into other companies’ devices tomorrow.

Market Opportunity & Strategy

Wearable Devices operates at the intersection of neural interfaces, wearable computing, and the rapidly expanding AR/XR sector. According to MarketsandMarkets, the global AR and VR market is projected to grow from $22.12 billion in 2024 to $96.32 billion by 2029, at a CAGR of 34.2%. The rising demand for natural, hands-free input methods positions neural wearables like Mudra as foundational components in spatial computing and smart environments.

Additionally, the health monitoring wearables market is gaining traction as neural biosignals become a promising data source. The company’s LMM (Large Motor Unit Action Potential Model) platform is being explored for predictive health monitoring, cognitive state tracking, and performance analytics. Government-level support, such as advocacy from the U.S. Secretary of Health and Human Services, further validates the sector’s momentum.

Combined with patent-protected technology and strategic alliances with companies like Qualcomm, TCL-RayNeo™, and Media Exceed, Wearable Devices is well-positioned to capture value across consumer, enterprise, and healthcare verticals.

The company’s phased market strategy anticipates this:

• Phase 1 – Enthusiast Consumer Adoption: Introduce Mudra Band as an add-on for Apple Watch (tapping into a passionate user base of early adopters and tech enthusiasts). Achieve proof-of-concept and get market feedback. This phase built brand credibility and seeded a community of users.
• Phase 2 – Expand Platform & Ecosystem: Launch Mudra Link for all users and open the Mudra SDK to developers and B2B partners. Focus on the XR/AR market and tech-savvy consumers, while enabling enterprise use-cases through the Developer Kit and strategic partnerships. The company is actively showcasing its tech to industry leaders and integrating with their platforms.
• Phase 3 – Leverage Data & Enter New Verticals: With a growing user base, Wearable Devices is collecting an invaluable dataset of neural signals and usage patterns. If data is the new oil for AI, neural signals will power the next computing revolution — enabling machines to understand human intent in real time. This fuels its Large Motor-Unit Action Potential Model (LMM) – a bio-signal intelligence platform that continuously learns from neural data to improve accuracy and enable new applications. One major new vertical is digital health and wellness: Wearable Devices is adapting its tech to track physiological and cognitive indicators from the wrist. Because the Mudra sensors capture muscle activation signals, they can potentially detect patterns related to stress, fatigue, focus, and even early signs of health conditions before traditional symptoms appear, and Wearable Devices recently announced it is expanding LMM into predictive health monitoring and cognitive analytics. This means the company could offer solutions for workplace productivity (measuring alertness), athletic training (muscle fatigue analytics), or preventive healthcare (flagging neuromuscular irregularities) – vastly broadening its addressable market. Through monitor applications, the vision is to go from controlling devices to also understanding the user, providing actionable bio-insights. The LMM platform’s AI continuously adapts to each individual’s neural profile, enabling truly personalized and proactive applications.
• Phase 4 – Ubiquitous Adoption via B2B Integration: Finally, Wearable Devices plans to drive mass adoption by aligning with major consumer tech players. By making its Mudra Data Platform available to enterprises, OEMs, and app developers, the company positions itself as the backbone for neural interaction services. By “laying the groundwork for the next neural frontier”, Wearable Devices is ensuring that when the tech giants move to adopt neural input, its platform is the mature, data-rich standard ready to be deployed.

Through these phased efforts, Wearable Devices balances B2C and B2B paths. It generates near-term revenues and user feedback via direct consumer product sales, while simultaneously developing long-term enterprise relationships and intellectual property value. This dual model not only diversifies revenue streams but also reinforces the technology’s credibility: consumer adoption demonstrates demand and usability, which in turn attracts enterprise interest, creating a virtuous cycle.

Leadership Team

Asher Dahan, Chief Executive Officer, co-founded Wearable Devices Ltd. in 2014 and has served as CEO and director since 2016. He is a seasoned executive with proven expertise in strategic planning, project execution, and business leadership. Asher oversees the company’s operations and resources, guiding major corporate decisions and long-term vision. Prior to founding Wearable Devices, he held engineering and leadership roles at Intel Haifa, specializing in high-speed interface validation. He holds a BSc in Electrical Engineering from Ort Braude College.

Guy Wagner, Chief Scientific Officer and President, co-founded Wearable Devices Ltd. in 2014 and has served on its board since inception. As CSO and President, Guy leads the company’s technological innovation and scientific direction. He is the main inventor behind the company’s core technology and brings multidisciplinary expertise in hardware design, biomedical signal processing, embedded programming, and sensor systems. He previously worked at Intel as a hardware engineer and holds a BSc in Electrical Engineering from Ort Braude College.

Leeor Langer, co-founder and CTO since 2016, is a leading expert in algorithms, machine learning, and signal and image processing. He has held senior R&D roles in the medical imaging and digital security sectors, including at Intel, and brings deep academic and industry experience. Leeor has authored several scientific papers and holds a BSc from the Technion and an MSc in Applied Mathematics from Tel Aviv University, graduating cum laude.

Wearable Devices Ltd. (NASDAQ: WLDS), closed Tuesday's trading session at $0.8336, off by 1.7097%, on 156,457 volume. The average volume for the last 3 months is 283,828 and the stock's 52-week low/high is $0.8201/$11.3999.

Recent News

• Wearable Devices Ltd. (NASDAQ: WLDS) - AINewsBreaks - Wearable Devices Ltd. (NASDAQ: WLDS) to Launch Mudra Experience Studio Developer Platform
• Wearable Devices Ltd. (NASDAQ: WLDS) Set to Capitalize in AI-Powered Wearable Space
• Wearable Devices Ltd. (NASDAQ: WLDS) Advances Touchless Control for AI and AR Glasses, Strengthening Its Position in Next-Gen Wearables

MAX Power Mining Corp. (CSE: MAXX) (OTC: MAXXF)

The QualityStocks Daily Newsletter would like to spotlight MAX Power Mining Corp. (CSE: MAXX) (OTC: MAXXF).

This article has been disseminated on behalf of MAX Power Mining and may include paid advertising.

MAX Power Mining (CSE: MAXX) (OTC: MAXXF) (FRANKFURT: 89N) announced an accelerated strategy to advance commercial evaluation of its Lawson Natural Hydrogen Discovery near Central Butte, Saskatchewan, and to pursue multiple strategic partnerships tied to the 475-kilometer Genesis Trend. The company has contracted Tetra Tech to conduct a 47-square-kilometer 3D seismic survey beginning the week of Feb. 23, 2026, with all permits secured, to support resource modeling and guide a confirmatory well. Concurrent laboratory analyses are underway, while more than 80 additional prospective structures along the Genesis Trend are being prioritized for a 2026 multi-well drill program, as the company engages potential end users interested in sourcing natural hydrogen pending proof of commercial deposits.

To view the full press release, visit https://ibn.fm/hNCp0

MAX Power Mining Corp. (CSE: MAXX) (OTC: MAXXF) is a Canadian mineral exploration company pioneering the development of natural hydrogen as a potential new primary energy source. As a first mover in this emerging sector, the company has assembled North America’s largest permitted land package targeting naturally occurring, emissions-free hydrogen accumulations in the earth’s subsurface.

MAX Power plans to commence Canada’s first dedicated deep drilling program for natural hydrogen in November 2025, starting on the 200-km-long Genesis Trend in southern Saskatchewan, with the goal of converting a discovery into the world’s first commercial natural hydrogen venture in 2026.

Backed by institutional partnerships and a highly experienced technical team, MAX Power continues to build a globally recognized brand in the natural hydrogen sector. Its massive land package in Saskatchewan currently comprises 1.3 million permitted acres with another 5.7 million acres under application.

Saskatchewan, a jurisdiction recognized for its supportive regulatory environment and clean energy innovation, features North America’s most advanced policy framework for the exploration and development of natural hydrogen. The province is also known for its spectacular resource endowment as the world’s leading potash provider, the top high-grade uranium producer in the world, and Canada’s second-largest oil producer. Saskatchewan is also Canada’s leader in helium production, geothermal energy and carbon capture.

The company’s head offices are in Saskatchewan’s two largest cities, Saskatoon and Regina.

Projects

Natural Hydrogen (Saskatchewan)

MAX Power holds multiple large land packages across Saskatchewan prospective for deposits of natural hydrogen, highlighted by the 200-km-long Genesis Trend and the 75-km-wide Grasslands Project.

Genesis features easy road, rail and power access and a proposed hydrogen hub on its eastern side where there is an abundance of potential end-users for natural hydrogen. Drilling is set to begin in early November 2025 at the Lawson target situated in the heart of Genesis. Canada’s first deep well for natural hydrogen is specifically designed to test a complete five-element hydrogen system interpreted to exist at Lawson: source rocks, migration pathways, reservoirs, seals, and traps. Data from vintage and proprietary 2D seismic, gravity and magnetic surveys, and subsurface mapping, among other geological and geophysical information, support the prospectivity of Lawson which lies adjacent to an extensive regional “Salt Barrier” offering excellent seal and trap conditions.

The Genesis Trend’s scalability is further demonstrated by the recent identification of the Lucky Lake target, approximately 50 km northwest of Lawson and one of at least 20 Lawson “look-a-likes” that is being investigated along the trend. Early interpretation suggests serpentinized rocks and structural features favorable for hydrogen generation exist at Lucky Lake.

At Grasslands, geologists are excited about a broad area in the vicinity of a well (“Climax”) near the U.S. border that was drilled a few years ago and inadvertently resulted in Canada’s first known deep subsurface occurrence of natural hydrogen, associated with a rare rock assemblage geologists refer to as “exotic terrane”. Permits covering an area stretching 75 km east-west and up to 10 km north-south were acquired by MAX Power next to this discovery, amplifying the company’s first-mover advantage. Adjacent to three sides of Grasslands are producing helium wells owned by privately-held North American Helium, demonstrating that this under-explored area of the province is highly prospective for clean gas. Drilling of a target at Grasslands is expected during Q1 2026.

Other MAX Power land packages are Rider 1, 2 and 3 in the southeast part of the province, and Choiceland in the north-central part of the province.

To enhance scientific rigor and accelerate development, MAX Power has established a multi-year strategic collaboration with the Petroleum Technology Research Centre (PTRC), a globally recognized leader in subsurface energy research based in Regina, Saskatchewan. This partnership complements the company’s relocation to Innovation Saskatchewan’s R+T Parks in Saskatoon and Regina, placing its technical and executive teams at the heart of the province’s academic, regulatory, and infrastructure ecosystem.

Critical Minerals

MAX Power’s other key asset is its Wilcox Lithium Project in mining-friendly Cochise County in southeast Arizona where first-ever diamond drilling in late 2023/early 2024 confirmed the discovery of near-surface lithium-rich clays over a broad area of the Willcox Playa. MAX Power’s property occurs within a nearly 4,000-acre corridor adjacent to U.S. Department of Defense land, and benefits from direct access through roads, rail and power infrastructure. The discovery was made just as lithium entered its final price downturn and is now being intensely revisited by the company in light of the turnaround in lithium and an emphasis on critical mineral resource development in the United States under the Trump administration.

Market Opportunity

According to company materials, the global hydrogen market is valued at approximately $250 billion and is expected to surpass $400 billion by 2030. Supporting this outlook, a study published in Science Advances (Dec. 2024) estimates that in-place natural hydrogen resources could meet global net-zero carbon goals for roughly 200 years. Closer to home, a feasibility study by the Transition Accelerator (April 2024) projects that the Regina-Moose Jaw Industrial Corridor (RMJIC) in Saskatchewan could support a C$708 million annual hydrogen market, with province-wide demand reaching as high as C$2.7 billion per year.

These projections underscore a compelling opportunity to establish a new energy economy centered around natural hydrogen—a low-cost, low-emission, and potentially naturally replenishing resource. MAX Power is well-positioned to lead this effort with proximity to infrastructure, favorable geology, and increasing institutional support.

Leadership Team

Mansoor Jan, CEO, brings more than two decades of international experience across mining operations, capital markets, and business development. He has held senior positions at BHP Australia, BHP Chile, and Rio Tinto, where he was responsible for advancing cross-border projects, driving mine optimization, and leading technology delivery across major jurisdictions. Mr. Jan holds a BA and MSc in Economics and a Master of Commerce from the University of New South Wales in Australia.

Neil McMillan, Director and Chair of the Audit Committee, is the former Chairman of the Board of Cameco, the world’s largest publicly traded uranium company. Mr. McMillan served on Cameco’s board for 16 years and is highly regarded within and outside the province for his decades of success there. He previously led Claude Resources as President and CEO, paving the way for its development into Saskatchewan’s only profitable gold miner which was bought out for more than $300 million by Silver Standard Resources in 2014.

Steve Halabura, Chief Geoscientist, has decades of successful experience in the province’s resource sector including a deep understanding of the geological controls on the accumulation of hydrogen, helium, and other industrial gases. He was also instrumental in the early formative stages of the only two Saskatchewan greenfield potash mines to come into existence in the 21st century, these being BHP’s Jansen Project and K+S’s Bethune mine. Jansen is the largest private investment ($14 billion) in Saskatchewan history and is located northeast of MAX Power’s Genesis Trend.

Tom Kishchuk, MAX Power’s Senior Strategic Advisor for Natural Hydrogen Development, is CEO for the Saskatchewan-based Global Institute for Energy, Mines and Society (GIEMS). He has over three decades of technical and business leadership in national and global organizations focused on the energy sector.

MAX Power Mining Corp. (OTC: MAXXF), closed Tuesday's trading session at $0.822, off by 0.1700267%, on 110,277 volume. The average volume for the last 3 months is 451,500 and the stock's 52-week low/high is $0.105/$0.8791.

Recent News

• MAX Power Mining Corp. (CSE: MAXX) (OTC: MAXXF) - MiningNewsBreaks - MAX Power Mining (CSE: MAXX) (OTC: MAXXF) (FRANKFURT: 89N) Accelerates Lawson Natural Hydrogen Development, Launches 3D Seismic Program
• Michigan Announces New Geologic Hydrogen Exploration Initiative
• Could 2026 Usher in Increased Trading of Tokenized Copper?

Datavault AI Inc. (NASDAQ: DVLT)

The QualityStocks Daily Newsletter would like to spotlight Datavault AI Inc. (NASDAQ: DVLT).

Datavault AI (NASDAQ: DVLT) announced that its board of directors has changed the distribution date for its previously announced dividend of warrants to purchase shares of common stock to Feb. 23, 2026, from Feb. 21, 2026, while the record date remains Jan. 7, 2026. The warrants will be issued to eligible record holders on the basis of one warrant for every 60 shares of common stock held, with each warrant exercisable at $5.00 per share for one year from the distribution date. Exercise will require holders to satisfy specified conditions, including holding one Dream Bowl Meme Coin II token per warrant in a Datavault account digital wallet, and will be subject to additional terms, transfer restrictions and potential adjustments as outlined in the warrant agreement and related SEC filings.

To view the full press release, visit https://ibn.fm/ImsDH

Datavault AI Inc. (NASDAQ: DVLT) is a pioneering leader in immersive, wireless sound technology, providing cutting-edge audio solutions for intelligent devices and next-generation home entertainment systems. The company collaborates with top consumer electronics (CE) brands and manufacturers, including industry giants like Harman International (a division of Samsung), LG, Hisense, TCL, Bang & Olufsen, and Platin Audio. WiSA Technologies delivers exceptional wireless sound experiences for high-definition content, including movies, music, sports, gaming, and esports, thereby enhancing the overall consumer experience in home entertainment.

As a founding member of WiSA™ (the Wireless Speaker and Audio Association), WiSA Technologies plays a critical role in defining wireless audio interoperability standards, ensuring seamless integration across devices and platforms. The company actively works with leading consumer electronics companies, technology providers, retailers, and ecosystem partners to promote and market spatial audio technologies, underscoring its commitment to advancing the future of audio and making high-quality, immersive sound accessible to a broader audience.

Headquartered in Beaverton, Oregon, WiSA Technologies extends its global reach with sales teams strategically located in Taiwan, China, Japan, Korea, and California. This international presence allows the company to effectively serve a diverse customer base and maintain strong relationships with key partners worldwide. By continuously innovating and setting new benchmarks in wireless audio, WiSA Technologies is well-positioned to remain at the forefront of the evolving home entertainment landscape.

The WiSA Association

The WiSA® Association, a wholly owned subsidiary of WiSA Technologies, is dedicated to promoting and standardizing spatial audio solutions for home entertainment, ensuring that immersive audio experiences are accessible to everyone. In collaboration with leading consumer electronics companies, technology providers, retailers, and ecosystem partners, the association works to advance wireless audio technology across various devices, making high-quality sound an integral part of modern home entertainment systems. As a key player in the industry, WiSA LLC, also known as the Wireless Speaker and Audio Association, is instrumental in fostering the adoption and integration of cutting-edge audio technologies.

Recently, the WiSA Association significantly expanded its influence by executing licensing agreements with leading HDTV brands, covering 43% of the HDTV market that uses the Android operating system, the most widely used OS in the market. By focusing on Android-based HDTVs and collaborating with speaker manufacturers, WiSA is actively building an ecosystem of WiSA E-enabled speaker systems, mirroring the success of its earlier WiSA HT technology. This strategic initiative, combined with WiSA E’s compatibility with multiple HDTV SoC providers and support for spatial audio formats like Dolby Atmos FlexConnect, positions the association at the forefront of transforming home audio experiences, driving widespread adoption across the home entertainment landscape.

Market Opportunity

From an investment perspective, WiSA Technologies Inc. is strategically positioned to capitalize on the growing demand for wireless and immersive audio experiences as consumer preferences shift toward high-definition home entertainment systems. As streaming services, gaming, and smart home technologies continue to expand, the need for seamless, high-quality audio solutions is becoming increasingly critical. WiSA Technologies, with its innovative wireless sound technology and strong partnerships with leading consumer electronics brands, is well-placed to capture a significant share of this expanding market, particularly as more consumers seek to enhance their home entertainment experiences.

Moreover, the company’s focus on setting industry standards through the WiSA Association further solidifies its role as a key player in the evolving audio landscape. By driving the adoption of wireless audio interoperability standards, WiSA Technologies not only ensures broad compatibility across devices but also positions itself as a leader in the market, capable of influencing future trends and technologies. This proactive approach, combined with its established global presence and collaborations with top-tier brands, provides WiSA Technologies with a strong foundation for sustained growth, making it an attractive opportunity for investors looking to gain exposure to the burgeoning home entertainment and smart audio sectors.

Leadership Team

Brett Moyer is the Chief Executive Officer, President, and Chairman of WiSA Technologies, Inc., and a founding member of the company. He has served in these leadership roles since August 2010. Prior to this, Mr. Moyer was the president and CEO of Focus Enhancements, Inc., where he oversaw the development and marketing of proprietary video technology. He has a rich background in consumer electronics, having held key positions at Zenith Electronics Inc., including Vice President and General Manager of its Commercial Products Division. Mr. Moyer also serves on the board of directors of Alliant International University and has previously served on the boards of HotChalk, Inc., and NeoMagic Corporation. He holds a Bachelor of Arts in Economics from Beloit College and an MBA in Finance and Accounting from Thunderbird School of Global Management.

Gary Williams is the Chief Accounting Officer and Vice President of Finance at WiSA Technologies, Inc., roles he has held since September 2019 and the company’s founding in August 2010, respectively. He previously served as the company’s Chief Financial Officer and Secretary until 2019. Mr. Williams has extensive experience in finance, having served as CFO of Quantum3D, Inc., and in similar roles at Focus Enhancements Inc. and Videonics Inc. He began his career in public accounting with Coopers & Lybrand LLP. Mr. Williams is a certified public accountant (inactive) and holds a bachelor’s degree in business administration with an emphasis in accounting from San Diego State University.

Datavault AI Inc. (NASDAQ: DVLT), closed Tuesday's trading session at $0.7463, off by 5.5316%, on 35,248,230 volume. The average volume for the last 3 months is 67,723,463 and the stock's 52-week low/high is $0.2512/$4.1.

Recent News

• Datavault AI Inc. (NASDAQ: DVLT) - InvestorNewsBreaks - Datavault AI Inc. (NASDAQ: DVLT) Changes Distribution Date for Warrant Dividend to Feb. 23, 2026
• Alibaba Unveils AI Designed for Use in Robotics
• TechMediaBreaks - Datavault AI Inc. (NASDAQ: DVLT) Featured by RADIO + TELEVISION BUSINESS REPORT for ADIO Engagement Platform and Real-Time Bias Meter

ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF)

The QualityStocks Daily Newsletter would like to spotlight ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF).

This article has been disseminated on behalf of ESGold Corp. and may include paid advertising.

ESGold (CSE: ESAU) (OTCQB: ESAUF) announced the appointment of Galen Carson, founder and principal of Caram Media Inc., to its advisory board, formalizing a strategic relationship that began in October 2024 and supported the company's capital markets strategy and investor positioning during a period of transformation. Since that time, ESGold has raised more than C$20 million to advance its fully permitted Montauban Gold-Silver Project toward production, expanded its shareholder base and increased market capitalization, as the company prepares for a fully funded path to initial gold and silver production in 2026 while continuing exploration across its Montauban land package.

To view the full press release, visit https://ibn.fm/lSMZl

ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) is a fully permitted, pre-production resource company on a clear path to near-term gold and silver production. With established infrastructure in place and a significant gold-silver resource, the company is uniquely positioned to generate near-term cash flow while unlocking the full potential of its Montauban Gold-Silver Project in Quebec—one of the top mining jurisdictions in the world.

ESGold is building a foundation for long-term growth through a dual-track strategy: cash-flow generation from tailings reprocessing to fund district-scale exploration.

The Montauban site, which operated as a mine for over 80 years, is now undergoing its first-ever systematic exploration program to determine just how large the remaining deposit may be. Near-term cash flow from tailings reprocessing will be used to fund exploration, with the goal of increasing the resource base and uncovering new discoveries across the expansive land package.

ESGold is advancing a scalable and replicable clean extraction model that turns legacy mine sites into revenue generating assets while setting a new industry benchmark for sustainable resource recovery.

The recent completion of a C$3.4M financing has enabled ESGold to initiate the final construction phase of its mill circuit—moving the company decisively toward production of gold and silver in Q3 2025.

Montauban Gold-Silver Project: Production Imminent

Located approximately 80 kilometers west of Quebec City, the Montauban Project is a past-producing gold-silver mine with surface and underground mineralization and over 900,000 tonnes of historical tailings. ESGold has invested over C$15 million to date, building out roads, power access, and a 16,000 sq. ft. processing facility. The company recently completed a C$3.4M financing to begin final construction of the mill circuit.

The company is fully permitted to enter into production that is expected to commence in Q3 2025 with a capacity of 500 tonnes per day, scaling to 1,000 tpd. An updated Preliminary Economic Assessment (PEA) is currently underway to reflect all-time high gold prices and the anticipated upside from the near-surface resource.

Parallels Between Broken Hill & Montauban

Broken Hill, discovered in 1883 in Australia, became the world’s largest source of silver, lead, and zinc—producing over $100 billion worth of metals. What made it unique was that the richest mineral zones were hidden deep underground in a twisted, boomerang-like shape, and it took decades to fully understand just how large the deposit really was.

Geologists now believe ESGold’s Montauban Project in Quebec may share similar traits. Like Broken Hill, it contains high-grade silver, lead, and zinc, along with gold—and sits within the same type of geological system known to host large, high-value mineral deposits. The rock formations, mineral assemblages, and structural complexity all suggest that Montauban could be hiding much more than what’s been historically uncovered. Academic studies now support this possible geological parallel, pointing to further evidence suggesting Montauban was formed under similar conditions as Broken Hill.

Exploration Upside

With production on the horizon, ESGold is advancing a major exploration campaign. Montauban has never undergone systematic modern exploration.

The company is currently completing a large-scale Ambient Noise Tomography (ANT) survey—a powerful 3D imaging technology that will define the size, shape, and continuity of the mineralized system. ANT is already showing strong results, with imaging going beyond the original 400m depth target and now expected to exceed 800m. This cutting-edge technology has the potential to reveal the full extent of the anomaly for the first time in Montauban’s 110-year history.

Scalable, Replicable, Clean Mining

Montauban is also part of a broader vision. Across Canada and globally, there are hundreds of orphaned or legacy mine sites that remain unrehabilitated despite containing valuable residual metals in tailings. Quebec alone is home to more than 259 of these sites, highlighting the scale of the opportunity. ESGold is advancing a scalable and replicable clean extraction model that transforms legacy sites into productive assets while setting a new benchmark for sustainable resource recovery.

The company has also performed testing that utilizes Dundee Sustainable Technologies’ CLEVR Process™, a proprietary non-cyanide extraction method that achieved 90.9% gold recovery in lab testing. This clean processing approach remains a valuable and scalable asset supporting ESGold’s near-term production and exploration growth strategy.

As a complement to its core mining operations, ESGold is developing clean technology solutions through a joint venture with DMCMS Inc. This initiative includes a polymer division that manufactures environmentally friendly products such as road stabilizers, dust suppressants, and other industrial blends—expanding the company’s sustainable commercial footprint.

Market Opportunity

ESGold is operating in a unique and specialized segment of the mining industry—reprocessing and revitalizing legacy mine sites. The Montauban Project offers both near-term cash flow and long-term growth potential by converting tailings into revenue while systematically exploring for additional high-value mineral endowments. The company’s established infrastructure, full permitting, and reclamation approvals reduce development risk and enhance execution timelines.

The broader green mining market is projected to reach $15.92 billion by 2030, according to Grand View Research. This growth is being driven by increased demand for responsible extraction methods, ESG-aligned practices, and critical mineral security. With construction underway at its fully permitted Montauban site—and exploration advancing along a Broken Hill-type geological model—ESGold is well positioned to emerge as Canada’s next premier gold and silver producer.

Leadership Team

Paul Mastantuono, Chief Executive Officer and Director, graduated with distinction from the University of Ottawa with a bachelor’s degree in social science, concentrating in criminology. He has extensive experience in the construction and transportation industries and has worked as an independent business consultant for various companies, including DNA Precious Metals Inc.

Brad Kitchen, President and Director, brings over 35 years of experience in investment banking and senior corporate management, primarily with resource-based companies. He has a detailed knowledge of regulatory, security, and tax issues, cross-border financings, and market influences, which he has applied to address business challenges for issuers and investors. Mr. Kitchen was also CEO of Eagle Hill Exploration, the company that generated in only five years the first Bankable Feasibility Study on the Windfall Lake Gold Project that was recently sold by Osisko Mining to Gold Fields for US$1.6 billion.

Andre Gautier, Senior Geologist and Director, brings over 47 years of experience in the Mining Exploration field and has worked in over 35 countries. His work experience includes entities such as: SOQUEM, Falconbridge Ltd., Noramco and Cambior Inc. Mr. Gauthier was president of MaxyGold Corp. (China), INCA Pacific Resources Inc., Lara Exploration Ltd., and Gold Holding Ltd. Mr. Gauthier also served as a Director of Vena Resources Inc., MaxyGold Corp., Lara Exploration Ltd., Western Union Peru, and Gold Holding Ltd., and from March 2015 until 2018, he served as interim Managing Director and CEO of Gold Holding Ltd., headquartered in Dubai (UAE). He has a BSC in Geology Eng. and MSC from UQAC (Chicoutimi, Quebec) and is an active member and leader of many mining and professional organizations (Canada, Peru, UAE, and China).

ESGold Corp. (OTCQB: ESAUF), closed Tuesday's trading session at $0.5208, off by 0.5689412%, on 64,077 volume. The average volume for the last 3 months is 118,290 and the stock's 52-week low/high is $0.139/$1.1.

Recent News

• ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) - MiningNewsBreaks - ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) Appoints Galen Carson to Advisory Board
• ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) Adds 144 Mining Claims for Mountauban Project After 3D Geological Model Points to Greater Potential
• ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) Marks Pivotal Milestone with Completed and Delivered Comprehensive ANT-Based 3D Geological Model for Montauban